New Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma
NCT ID NCT07369895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new cell therapy called O&D-001 for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and GPRC5D). The study will enroll 18 adults and focus on safety and dosing, with some early signs of effectiveness also tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
O&D-001 CAR T cells (a type of immune cell therapy that targets two proteins on cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with multiple myeloma that has not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 18 participants, so it is too soon to know if it will be safe or effective. There are risks of serious side effects from the cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••